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Background: CD36, a class B scavenger receptor, participates in the pathogenesis of metabolic dysregulation such
as insulin resistance, hepatic steatosis, and atherosclerosis. Persistent hepatitis C virus (HCV) infection often evokes
these metabolic abnormalities. The primary purpose of this study was to investigate the role of CD36 in the
pathogenesis of insulin resistance and hepatic steatosis caused by chronic HCV infection.
Methods: Forty-five patients with HCV-related chronic liver disease (CLD-C) were enrolled in this study. CD36
expression in the liver specimen was examined by an immunohistochemical procedure. The concentrations of
circulating soluble form of CD36 (sCD36) and oxLDL were determined by the enzyme-linked innunosorbent assay.
Insulin resistance was estimated by the values of HOMA-IR.
Results: Moderate to extensive hepatic CD36 expression was observed in the sinusoids of all enrolled CLD-C
patients. CD36-positive sinusoids appeared to be identical to Kupffer cells. The severity of CD36 expression in the
hepatic sinusoids was significantly correlated with the sCD36 level in sera of patients with CLD-C. The serum sCD36
levels were significantly correlated with body mass index and serum oxLDL levels in those patients. However, the
serum sCD36 concentrations were independent of the values of HOMA-IR and the severity of hepatic steatosis.
Conclusions: These data suggest that the serum sCD36 levels reflect the severity of CD36 expression on the
Kupffer cells in patients with CLD-C, and that the serum sCD36 levels were associated with obesity, although the
levels were independent of insulin resistance and hepatic steatosis in those patients.
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An estimated 180 million people in the world are
chronically infected with hepatitis C virus (HCV). The
virus induces a spectrum of chronic liver diseases from
chronic hepatitis to liver cirrhosis, and ultimately to
hepatocellular carcinoma (HCC) [1].
Persistent HCV infection often evokes numerous kinds
of metabolic abnormalities, including insulin resistance,
hepatic steatosis, dyslipidemia and iron overload [2-4].
These metabolic abnormalities, which are induced by* Correspondence: thimoto@med.kagawa-u.ac.jp
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reproduction in any medium, provided the orthe direct actions of HCV itself [5] and/or through various
host factors [2-4], are involved in the pathogenesis of
chronic liver damage. Insulin resistance, hepatic steatosis
and iron overload have also been considered to be predict-
ive risk factors refractory to antiviral treatments like
pegylated interferon (PEG-IFN) alone or PEG-IFN plus
ribavirin in patients with chronic hepatitis C (CH-C) [6-8].
Moreover, insulin resistance seems to be associated with
not only hepatic fibrosis but also with carcinogenesis in
those patients [9,10]. Impairment of insulin receptor
substrate-1 (IRS-1) by HCV core protein directly or
through a variety of cytokines and trace elements may
account for insulin resistance in those patients [11]. We
previously revealed that zinc and selenium deficiencyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of the enrolled patients
with CLD-C
Age (y.o.) 56.3 ± 9.2(34–74)
Gender (Male/Female) 25/20
BMI 23.3 ± 3.4(17.0-31.9)
Staging (F1/F2/F3/F4) 16/16/7/6
Steatosis (grade 0/1/2) 26/13/6
HCV genotype (1b/2a/2b) 28/13/4
Loads of HCV-RNA (KIU/ml) 2537 ± 2766 (48–10000)
Values of HOMA-IR 2.18 ± 1.40 (0.51-5.53)
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HCV-related chronic liver disease (CLD-C) [12,13].
Recent studies have revealed that CD36, also known as
fatty acid translocase (FAT), is expressed on the surface
of a variety of cells including adipocytes, skeletal muscle
cells, platelets, monocytes, endothelial cells, and macro-
phages as a receptor for oxidized low-density lipoprotein
(oxLDL) [14,15]. CD36 has been proposed to be a surro-
gate of macrophage activation and inflammation [16].
Moreover, it has been widely studied that CD36 plays a
pivotal role in the metabolic dysregulation including
obesity, insulin resistance and atherosclerosis [14,17].
Therefore, CD36 expression on the surface of monocytes
and macrophages is up-regulated by oxLDL in patients
with type 2 diabetes mellitus (DM) [18]. CD36 also has
been considered to contribute to the progression of
hepatic steatosis [19,20]. In contrast, one study has
suggested that CD36 deficiency, characterized by the
absence of CD36 expression in peripheral platelets
alone or both platelets and monocytes, is associated
with insulin resistance in patients with coronary heart
diseases [21].
CD36 is in the category for the class B scavenger
receptor [14], and the human scavenger receptor class B
type I (SR-BI) has been shown to be a novel candidate
receptor for HCV of genotypes 1a and 1b [22]. Miquilena-
Colina and colleagues demonstrated that the expression of
CD36 was up-regulated in the liver of patients with
nonalcoholic steatohepatitis (NASH) and patients infected
with HCV of genotype 1 [23].
More recently, a soluble form of CD36 (sCD36) was
identified in human plasma as a novel biomarker for
type 2 DM [24]. Handberg and colleagues proposed that
higher levels of sCD36 predicted the development of
type 2 DM irrespective of age, gender and obesity [25].
They also speculated that sCD36 might be circulating in
microparticles derived from monocytes, platelets, or
endothelial cells [25].
The primary purposes of this study were to elucidate
the role of CD36 in the pathogenesis of insulin resistance
caused by persistent HCV infection, to investigate the
changes in the circulating sCD36 and oxLDL levels by
antiviral treatments, and to determine whether or not




Forty-five non-diabetic patients with CLD-C, all of whom
were admitted in the Hospital of Kagawa University
School of Medicine, and had detectable serum HCV-RNA
by polymerase chain reaction (PCR) and showed histo-
logical findings compatible with chronic hepatitis or liver
cirrhosis, were randomly selected for participation in thisstudy (Table 1). Eight cases of normal healthy controls
(NHCs) were also assigned to the comparison group. Blood
samples were drawn in the morning with fasting before
anti-viral treatments. This clinical trial was approved by
the ethics committee of Kagawa University School of
Medicine. Fully informed consent was obtained from
each participant.
Laboratory assessments
The serum alanine aminotransferase (ALT) levels were
determined by the standard laboratory technique. The
circulating sCD36 and oxLDL concentrations were
determined by a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (Cusabio Biotech Co.
Ltd, Wuhan, China). The minimums detectable dose of
sCD36 and oxLDL are 4 pg/ml and 0.039 μmol/ml, re-
spectively. Quantitative detection of serum HCV-RNA
was performed by the Amplicor-HCV monitor assay
(Roche Molecular Diagnostics, Tokyo, Japan) [26] or
COBAS TaqMan HCV assay (TaqMan) (Rosche Diagnostics,
Tokyo, Japan) [27]. The values measured by the TaqMan
assay were adjusted to those determined by the Amplicor-
HCV monitor assay. The HCV-genotype was determined
by the HCV-RNA genotyping assay system (Home Brew
SRL Inc., Tokyo, Japan) [28].
In addition, insulin resistance was determined by the
values of the Homeostasis Model for Assessment of
Insulin Resistance (HOMA-IR) method using the following
equation: HOMA-IR = Fasting insulin (μU/ml) × fasting
glucose (mg/dl)/405. Insulin resistance was defined as the
values of HOMA-IR exceeding 2.0. Body mass index (BMI)
was estimated as a hallmark of obesity. Obesity was defined
as BMI over 25.0.
Histological assessments
Liver tissue specimens were obtained by liver biopsy
under the guidance of ultrasound, using 16-gauge needles,
before antiviral treatments. The tissue samples were fixed
in 10% formalin and embedded in paraffin. The tissue
sections were stained with hematoxylin and eosin for
morphological evaluation. Hepatic fibrosis was evaluated
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[29], the standard criterion for the histological assessment
of chronic hepatitis in Japan. Briefly, the staging of hepatic
fibrosis was scored as follows: F0, no fibrosis in the liver
specimen; F1, portal expansion; F2, bridging fibrosis; F3,
bridging fibrosis with lobular distortion; and F4, liver
cirrhosis. The severity of hepatic steatosis was graded
on the basis of the classification proposed by Brunt and
colleagues [30]. In brief, steatosis observed in none, less
than 33%, 33-66%, or more than 66% of hepatocytes was
defined as grade 0, 1, 2, or 3, respectively.
Immunohistochemical procedure
The expression of CD36 protein in the liver specimens of
the enrolled patients with CLD-C was examined by an im-
munohistochemical procedure. In brief, each tissue section
was deparaffinized, then washed by phosphate-buffered
saline (PBS) and incubated with mouse anti-human
monoclonal antibody to CD36 (OriGene Technology, Inc,
Rockville, MD, USA) as a primary antibody. After washing
with PBS, the tissue section was reacted with biotinylated
goat anti-mouse polyclonal antibody. Thereafter, color was
developed with diaminobenzine (DAB). Counter staining
was performed with hematoxylin. The degree of hepatic
CD36 expression was classified into three categories: none,
moderate and extensive.
For dual immunofluorescence staining, the tissue sections
were incubated with mouse anti-CD14 antibody (1:400,
Santa Cruz Biotech, CA, USA), followed by incubation in
Alexa Fluor 594-conjugated anti-mouse IgG (Molecular
Probes, Eugene, OR, USA). In addition, the sections were
incubated with rabbit anti-CD36 antibody (1:50, Novus,
Littleton, CO, USA), followed by incubation in Alexa
Fluor 488-conjugated anti-rabbit IgG (Molecular Probes).
Then, the sections were incubated in Monomeric Cyanine
Nucleic Acid Stains (TO-PRO-3, Molecular Probes), which
was diluted in phosphate-buffered saline (PBS). The fluor-
escent signals were viewed under a confocal microscope
(Carl Zeiss LSM700, Oberkochen, Germany). As a control
experiment, we performed an identical immunohistochem-
ical procedure by omitting the primary antibodies.
Diagnosis of CD36 deficiency
Fluorescein isothiocyanate (FITC)-conjugated anti-human
monoclonal antibody against CD36 (Beckman Coulter, KK,
Shizuoka, Japan) was used to detect CD36 in immunofluor-
escent flow cytometry. The signal from the anti-CD36
was gated with phycoerythrin (PE)-conjugated anti-human
monoclonal antibody against CD41 (Beckman Coulter KK,
Shizuoka,Japan), a specific marker for platelets, or PE-
conjugated anti-human monoclonal antibody against CD14
(Beckman Coulter KK, Shizuoka, Japan), a specific marker
for monocytes. For the platelet experiment, platelet-rich
plasmas were analyzed.CD36 deficiency was defined as the absence of CD36
molecules on the surface of peripheral monocytes and
platelets (type 1), or peripheral platelets alone (type 2),
by flow cytometry analysis.Statistical analyses
Data values are represented as means ± standard deviations
(SDs). The Mann–Whitney U-test was used for the
comparison of variables between two groups, while the
Bonferroni/Dunn method was carried out for comparisons
among three groups. The relationships between quantita-
tive variables were analazed by Pearson’s test. The paired
t-test was used to compare the valuables before and at the
end of antiviral treatments. P values less than 0.05 were
considered to indicate significance.Results
Clinical characteristics of the enrolled patients with CLD-C
As shown in Table 1, the ages at entry in the enrolled
patients ranged from 34 to 74 years old (y.o.). Among
those patients, 25 were male, and 20 were female. The
average BMI in the enrolled patients was 23.3 ± 3.4.
Sixteen of 45 (35.6%) patients with CLD-C were in the
category of obesity. The severity of hepatic fibrosis in
the enrolled patients was evaluated as follows: F1 in 16
patients, F2 in 16, F3 in 7, and F4 in 6. In the light of
hepatic steatosis, 26 patients with CLD-C had no hepatic
steatosis (grade 0), while 13 and 6 patients had hepatic
steatosis grades 1 and grade 2, respectively. None of those
patients had grade 3 hepatic steatosis. HCV-genotypes of
the enrolled patients were 1b in 28 patients, 2a in 13
patients, and 2b in 4 patients. The loads of HCV-RNA in
those patients ranged from 48 to 10,000 KIU/ml. The
mean value of HOMA-IR in the enrolled patients was
2.18 ± 1.40. Nineteen of 45 (42.2%) patients with CLD-C
fulfilled the criterion for insulin resistance.
In contrast, 3 males and 5 females were in the group
of NHCs. Mean age in the NHC group was 43.8 ± 6.2 y.o.
The BMI in each NHC case was all less than 25.Hepatic CD36 expression
The localization and severity of CD36 expression in liver
specimens of the 38 enrolled patients with CLD-C were
examined by immunohistochemical techniques. All of the
liver specimens had some expression of CD36 protein in
the sinusoids: moderate expression in 19 patients and
extensive expression in the other 19 (Figure 1a and 1b).
The CD36-positive sinusoids were stained with anti-CD14,
suggesting that Kupffer cells were candidates for CD36-
positive sinusoids (Figure 2). However, none of the patients
had CD36 expression in the hepatocytes.
(a) (b)
Figure 1 Representative figures of the hepatic CD36 expression by an immunohistochemical staining. (a) Moderate and (b) extensive
degrees of CD36 protein were observed in the sinusoids. (original magnification × 100).
Himoto et al. Diabetology & Metabolic Syndrome 2013, 5:51 Page 4 of 10
http://www.dmsjournal.com/content/5/1/51Correlation between the severity of CD36 expression
in the liver and the circulating sCD36 concentration
The serum sCD36 levels were compared between the
groups with moderate and extensive CD36 expressions
in the liver. As shown in Figure 3, the mean circulating
sCD36 level was significantly higher in the group with
extensive hepatic CD36 expression than that in the group
with moderate hepatic CD36 expression (250.1 ± 96.8 vs
167.2 ± 54.6 pg/ml, p = 0.0066). This result indicated that
the circulating sCD36 might reflect the severity of CD36(a)
(c)
Figure 2 Representative figures of dual staining with anti-CD14 and a
with anti-CD36 (b) immunohistochemical staining with anti-CD14, (c) nucle
(original magnification × 100).expression in the hepatic sinusoids of the enrolled patients
with CLD-C.
Correlation between the circulating sCD36 concentrations
and clinical parameters
The relationships between serum sCD36 levels and oxLDL,
ALT, BMI or hepatic steatosis were investigated in patients
with CLD-C. The serum sCD36 levels were roughly
correlated with BMI in the enrolled patients (r = 0.336,
p = 0.0242, Figure 4a). The serum sCD36 levels were(b)
(d)
nti-CD36 in the liver specimens. (a) immunohistochemical staining
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Figure 3 Relationship between hepatic CD36 expression and
serum sCD36 level. Mean serum sCD36 level in the group with
extensive hepatic expression of CD36 was significantly higher than











































































Figure 4 Relationship between circulating sCD36 level and BMI, serum
HCV-genotype or load of HCV-RNA. (a,b) Serum sCD36 levels were roug
levels were not associated with the severity of the hepatic steatosis or HCV
The boxes represent the values within the 25th and 75th percentiles. The h
independent of serum ALT levels and loads of HCV-RNA.
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(r = 0.422, p = 0.0016, Figure 4b). However, the circulating
sCD36 concentrations were independent of the severity of
hepatic steatosis (Figure 4c) and the serum ALT levels
(Figure 4d) in the enrolled patients. Neither HCV-genotypes
nor loads of HCV-RNA were correlated with the circulat-
ing sCD36 concentrations (Figure 4e and 4f).
Comparisons of the circulating sCD36 and oxLDL
concentrations between CLD-C patients and NHC
The serum sCD36 and oxLDL levels were compared
between CLD-C patients and NHCs. Patients with CLD-C
were divided into obese and non-obese groups, because
the serum sCD36 levels were dependent on obesity. Obese
patients with CLD-C had significantly higher circulating
sCD36 concentrations than those in NHCs (254.7 ± 123.5
vs 153.7 ± 44.6 pg/ml, p = 0.0112, Figure 5a). The serum
sCD36 levels were also higher in obese patients than in
non-obese patients (254.7 ± 123.5 vs 190.5 ± 73.0 pg/ml,
p = 0.0241, Figure 5a). Similarly, the serum oxLDL levels
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Figure 5 Comparisons of serum sCD36 and oxLDL levels between patients with CLD-C and NHCs. (a) The serum sCD36 levels were
significantly higher in obese patients with CLD-C than in NHCs. Obese patients also had significantly higher serum sCD36 levels than non-obese
patients. (b) The serum oxLDL levels were similarly higher in obese patients than in NHCs. However, no significant difference in the serum oxLDL
level was found between obese and non-obese patients.
Himoto et al. Diabetology & Metabolic Syndrome 2013, 5:51 Page 6 of 10
http://www.dmsjournal.com/content/5/1/51than those in NHC (5.54 ± 4.15 vs 0.46 ± 0.44 μmol/ml,
p = 0.0029, Figure 5b). However, no significant difference
in serum oxLDL levels was found between obese and non-
obese CLD-C patients (5.54 ± 4.15 vs 4.46 ± 3.97 μmol/l,
p = 0.3587, Figure 5b).Correlation between insulin resistance and the circulating
sCD36 or ox LDL concentrations
Next, we examined the relationshisp between insulin
resistance and the circulating sCD36 or oxLDL levels in
patients with CLD-C. No significant correlations were
apparent between the circulating sCD36 concentrations
and the values of HOMA-IR in those patients (r = 0.015,


























Figure 6 Relationship between the values of HOMA-IR and serum (a)
values of HOMA-IR were not associated with serum sCD36 and oxLDL leveindependent of the values of HOMA-IR in those patients
(r = −0.265, p = 0.0787, Figure 6b).
Changes in the circulating sCD36 and oxLDL
concentrations by antiviral treatments
The levels of circulating sCD36 and oxLDL were analyzed
before and at the end of antiviral treatments such as
pegylated interferon (PEG-IFN) alone or PEG-IFN plus
ribavirin in eleven patients with chronic hepatitis C
(CH-C), because these 11cases had paired serum samples
before and the end of antiviral treatments. Among the
patients with CH-C, 6 patients were genotype 1b, 3 patients
were genotype 2a, and 2 patients were genotype 2b. Nine





























sCD 36 levels or (b) oxLDL levels in patients with CLD-C. The
ls.
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SVR were significantly decreased by the PEG-IFN-based
treatments (209.8 ± 65.7 vs 148.5 ± 43.8 pg/ml, p = 0.0212),
while the sCD36 levels in the other 2 CH-C patients with-
out SVR were increased. Therefore, the circulating sCD36
concentrations at the end of the treatments tended to be
decreased (192.1 ± 70.9 vs 155.7 ± 43.6 pg/ml, p = 0.1635,
Figure 7a) in 11 patients with CH-C. The serum oxLDL
levels also tended to be decreased by antiviral treatments
(2.95 ± 2.99 vs 1.61 ± 1.06 μmol/ml, p = 0.0598, Figure 7b).
Prevalence of CD36 deficiency
Peripheral blood was collected from 20 of the 45 patients
with CLD-C. One of the 20 (5.0%) patients with CLD-C
lacked CD36 expression on the surface of the peripheral
platelets (Figure 8); this patient was diagnosed as CD36
deficiency type 2. He was infected with HCV of genotype
2a. The value of HOMA-IR in the patient was 1.68,
indicating that the patient was not associated with insulin
resistance. None of the patients with CLD-C fulfilled the
category of CD36 deficiency type 1.
Discussion
This study demonstrated that hepatic expression of
CD36 was observed on the hepatic sinusoids of patients
with CLD-C, and that the expression of CD36 in the
sinusoids was colocalized with CD14 in patients with
CLD-C, suggesting that CD36-positive sinusoids were
identical to Kupffer cells. Imajo and colleagues docu-
mented CD14-positive Kupffer cells in the experimental




























Figure 7 Changes in the serum (a) sCD36 and (b) oxLDL levels by the
decreased by antiviral treatments. The horizontal bars represent the averagthat the severity of CD36 expression generally paralleled
the circulating sCD36 concentrations in patients with
CLD-C. Alkhatatbeh and colleagues documented that
sCD36 in plasma was associated with circulating micro-
particles [32]. Therefore, we assumed that sCD36 might
circulate in microparticles derived from Kupffer cells in
those patients. Surprisingly, no expression of the CD36
protein on hepatocytes was found in the liver specimens
of patients with CLD-C.
Recently, Miquilena-Colina and colleagues elucidated
that the CD36 protein was largely expressed at the plasma
membrane of hepatocytes in patients with HCV genotype
1 and hepatic steatosis, and patients with NASH [23],
while the expression was predominantly located in the
cytoplasm of hepatocytes in CH-C patients without hepatic
steatosis. They described that weak expression of CD36
was also observed in the cytoplasm of scattered hepatocytes
even in the normal liver. It is of interest that hepatic
steatosis affected the localization of CD36 protein in the
hepatocytes. However, these findings differed from our
results that CD36 expression was not observed in the
hepatocytes but the sinusoids. The reason for the discrep-
ancy between our results and theirs remains unclear.
The present study also exhibited that the circulating
sCD36 and oxLDL levels were obviously elevated in
obese patients with CLD-C compared to those in NHCs.
Nakhjavani and colleagues also confirmed significant higher
level of oxLDL in patients with CH-C than in NHCs [33].
Increased serum oxLDL levels seemed to be derived from
oxidative stress by persistent HCV infection. The serum





























antiviral treatments. Serum sCD36 and oxLDL levels tended to be
es.
Figure 8 Representative figure of CD36 deficiency type 2 by flow cytometry. (a) A lack of CD36 expression on the surface of peripheral
platelets was observed. (b) CD36 was normally expressed on the peripheral monocytes.
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the circulating sCD36 levels were associated with obesity
in patients with CLD-C, which supports the previous
evidence of a close correlation between the serum sCD36
level and BMI in patients with type 2 DM [24].
A previous article documented that the circulating
sCD36 levels were associated with insulin resistance
in non-diabetic obese patients [24]. It has been well
established that the binding of oxLDL to CD36 results in
the activation of c-Jun N-terminal kinase (JNK) and sub-
sequent disruption of insulin signaling in both adipocytes
and macrophages [34]. However, the current study did not
reveal a significant correlation between the values of
HOMA-IR and the circulating sCD36 levels in patients
with CLD-C, although the serum sCD36 levels were
higher in those patients than in NHCs.
A recent study proposed the circulating sCD36 level
as a novel hallmark for liver damage in subjects with
altered glucose tolerance [35]. However, we could not
demonstrate a relation between the circulating sCD36
level and the liver damage in patients with CLD-C. The
finding that most patients with liver cirrhosis develop
severe insulin resistance, while the necroinflammation in
those patients is attenuated may account for the lack of
correlation between the serum sCD36 level and the sever-
ity of liver damage in patients with CLD-C.
It has been recently recognized that CD36 plays an
indispensible role in the regulation of tissue uptake of
free fat acid from plasma [36]. The expression of CD36
was decreased in adipose tissue, but increased in the
liver. Such change in CD36 distribution might be involved
in increased intrahepatic triglyceride content, and sub-
sequently hepatic steatosis [36]. However, we could not
provide the evidence that the circulating sCD36 level
was associated with the severity of hepatic steatosis inthe present study. Further examinations are required
to clarify the discrepancy.
We postulated that the sCD36 levels are associated
with infection by HCV genotype 1b, because the human
SR-BI appeared to be a novel candidate receptor for
the HCV of genotype 1b. However, the circulating sCD36
concentrations were independent of HCV genotypes in
this study. The loads of HCV-RNA did not affect the
serum sCD36 levels in those patients, either. These results
may indicate that sCD36 levels are regulated by host
factors rather than the viral factors themselves.
SR-BI has been well known as a key host factor for
HCV entry by way of HCV-CD81 interaction [37]. The
serum sCD36 levels were decreased by the PEG-IFN-
based anti-viral treatments among patients with CH-C
who achieved SVR. This result supported the finding by
Murao and colleagues that exogenous IFN-α suppressed
the expression of human SR-BI [38]. They demonstrated
that the expression of human SRB-I was decreased through
the inhibition of the signal transducer and activator of
transcription (STAT) 1/STAT2 pathway. Therefore, the
reduction of the circulating sCD36 level by antiviral
treatments may imply the successful eradication of
HCV. Likewise, this study also showed that the serum
oxLDL levels tended to be decreased by antiviral treat-
ments in patients with CH-C.
CD36 deficiency type 1 and type 2 were previously ob-
served in 1.0% and 5.8% of healthy volunteers, respectively
[39]. The present study revealed that the prevalence of
CD36 deficiency type 2 in patients with CLD-C was
approximately equivalent to that in NHCs, although
flow cytometric analysis was performed in only 20 patients
with CLD-C. The relationship between CD36 deficiency
and insulin resistance remains controversial. One study
revealed the association of CD36 deficiency with insulin
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while another study did not [40]. There was only one
patient who fulfilled the category of CD36 deficiency
type 2. Therefore, we could not elucidate the relationship
between CD36 deficiency and insulin resistance in patients
with CLD-C.
There are some limitations in this study. First, the
number of flow cytometry tested for CD36 deficiency, and
the number of paired samples to determine sCD 36 and
oxLDL levels before and at the end of antiviral treatments,
may be insufficient for the statistical analyses. However, a
definite tendency was shown in each parameter.
Second, we could not compare hepatic expression of
CD36 between patients with CLD and NHCs, because
liver tissue specimens were not obtained from NHCs.
Therefore, we speculated that the severity of hepatic
CD36 expression was more extensive in obese patients
with CLD-C than in NHCs through the result that the
serum sCD36 levels were significantly higher in obese
patients with CLD than in NHCs.
Conclusion
We concluded that the serum sCD36 levels generally
substituted for the severity of CD36 expression on the
Kupffer cells in patients with CLD-C, and that serum
sCD36 levels were dependent on obesity, but were neither
associated with insulin resistance nor hepatic steatosis in
those patients.
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